Avelumab Exposure and Merkel Cell Carcinoma: A Review of Causation Evidence

Legacy of General Health and Science Information

The legacy heritage of general health and science information dissemination has long served as a foundational resource for public awareness and education. This broad context encompasses a wide range of topics, from preventive care to environmental health factors, providing a baseline understanding of how various exposures may influence well-being. Within this framework, the transition to more specialized areas of concern often begins with recognized patterns of risk assessment and occupational safety considerations. In the domain of mass production environments, where chemical and biological exposures are routine, the shift from general health context to specific occupational hazards becomes particularly relevant. The bridge concept here involves moving from broad health literacy to focused scrutiny of workplace-related exposures, such as those involving therapeutic agents like Avelumab. While general health information may cover drug mechanisms in a clinical setting, the occupational exposure concern arises when these substances are handled during manufacturing processes. This pivot requires acknowledging that production workers may encounter compounds not typically considered in public health discussions. The transition thus reframes the legacy heritage of general science information toward a targeted examination of how occupational exposure to specific agents, including those used in immunotherapy, could pose distinct risks. The focus remains on the exposure pathway itself, without delving into disease-specific mechanistic claims, preserving a neutral academic tone that prioritizes the shift in context from general awareness to industrial hygiene considerations.

Bridge from General Health to Occupational Exposure

Building on the legacy of general health information, this section explicitly bridges to the specific context of occupational exposure to Avelumab. Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma has a rising incidence and high mortality. Approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). The standard treatment of metastatic MCC includes anti-PD-1/PD-L1 immune checkpoint inhibitors such as avelumab, which compared with conventional chemotherapy show better overall response rates and longer duration of responses (https://pubmed.ncbi.nlm.nih.gov/34445385/). Nevertheless, about 50% of patients do not respond or develop immune-related adverse events (irAEs) due to diverse mechanisms, such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). Checkpoint inhibitors including avelumab are known to cause overactivation of the immune system, leading to immune-related adverse events (https://pubmed.ncbi.nlm.nih.gov/31543781/). For example, a case report described hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This illustrates the potential for avelumab to trigger or exacerbate immune-mediated conditions.

Evidence on Causation Between Avelumab and Merkel Cell Carcinoma

Regarding causation between avelumab exposure and Merkel cell carcinoma, the evidence does not indicate that avelumab causes MCC. Rather, avelumab is a treatment for existing MCC. The literature consistently describes avelumab as a therapeutic agent for metastatic MCC, not as a causative factor (https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). For patients who are refractory to avelumab, treatment options include combined ipilimumab plus nivolumab, which has shown responses in avelumab-refractory patients (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). In a multicenter study of the prospective skin cancer registry ADOREG, immune checkpoint inhibition has significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). The timeline between avelumab exposure and documented harm is relevant only in the context of adverse events during treatment, not for MCC causation. For example, the case of hypercalcaemia due to sarcoidosis occurred during avelumab treatment for metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/31543781/). There is no evidence linking avelumab exposure to the development of MCC; instead, avelumab is used to treat MCC.

Risk Context and Adequacy of Warnings

Risk anchors regarding adequacy of warnings: The prescribing information for avelumab includes warnings about immune-related adverse events, as checkpoint inhibitors are known to cause overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, the evidence does not suggest that avelumab causes MCC, so warnings about MCC causation are not applicable. For affected patients, causation considerations should focus on the natural history of MCC and the role of avelumab as a treatment, not as a trigger. In summary, the evidence supports that avelumab is an effective treatment for metastatic MCC, with a known profile of immune-related adverse events. There is no evidence that avelumab exposure is linked to the causation of Merkel cell carcinoma. The mechanistic pathways discussed in the literature relate to avelumab's action as a PD-L1 inhibitor in treating MCC, not to causing the disease.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does Avelumab cause Merkel cell carcinoma?

No, the evidence does not indicate that Avelumab causes Merkel cell carcinoma. Avelumab is a treatment for existing MCC, not a causative factor (https://pubmed.ncbi.nlm.nih.gov/29799096/; https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/).

What are the known risks of Avelumab treatment?

Avelumab can cause immune-related adverse events due to overactivation of the immune system, such as hypercalcaemia secondary to sarcoidosis (https://pubmed.ncbi.nlm.nih.gov/31543781/). These are manageable with corticosteroids and do not indicate causation of MCC.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.